HCW Biologics Secures $10 Million Debt Financing from Streeterville Capital
HCW Biologics Inc. entered into a Notes Purchase Agreement with Streeterville Capital, LLC on November 3, 2026, issuing two secured promissory notes totaling $10.2 million in original principal for gross proceeds of $10.0 million. The transaction includes a Promissory Note A-1 of $3.2 million (with $240,000 OID and $30,000 transaction costs) bearing 8% interest and a Promissory Note B of $7.0 million bearing 5% interest, both maturing in 24 months. Net cash of $3.0 million was received at closing on November 4,...
Key takeaways
Company closed $10.0 million debt financing on November 4, 2026 with net cash of $3.0 million received at closing
A-1 Note carries 8% annual interest, 24-month maturity, $240,000 original issue discount, and 10% prepayment premium
B Note carries 5% annual interest, 24-month maturity, $7.0 million held in DACA-controlled account with conditional release provisions
Monitoring Fee of approximately 17.6% of outstanding balance will be added to A-1 Note if outstanding on 90th day following closing
Lender has Monthly Redemption rights of up to $125,000 per calendar month and Limited Redemption rights beginning 6 months after closing
Trigger Events (payment default, insolvency, covenant breach, fundamental transaction) can increase note balances by 10% for Major Trigger Events or 5% for Minor Trigger Events
Maxim Group LLC served as placement agent receiving 7.0% cash fee on gross proceeds plus up to $30,000 in expense reimbursement
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow HCWB in real time
Get material earnings, filing, IR, and earnings-call alerts by email.